Review
Biochemistry & Molecular Biology
Pia van der Laan, Winan J. van Houdt, Daan van den Broek, Neeltje Steeghs, Winette T. A. van der Graaf
Summary: Sarcomas, rare tumors with high heterogeneity, present an opportunity for liquid biopsy as a promising diagnostic tool; however, there are technical challenges that need to be addressed in order to implement this method effectively in clinical practice.
Article
Pathology
Andrea Moreno-Manuel, Silvia Calabuig-Farinas, Antonia Obrador-Hevia, Ana Blasco, Amaya Fernandez-Diaz, Rafael Sirera, Carlos Camps, Eloisa Jantus-Lewintre
Summary: In oncology, precision medicine has been achieved through biomarker-driven therapies and the use of liquid biopsy technology, particularly through the sensitive and efficient detection method of digital PCR (dPCR). Despite some challenges like multiplexing capacity and protocol standardization, dPCR is considered one of the most sensitive methods for LB analysis and complements next generation sequencing (NGS) in treatment monitoring and minimal residual disease assessment.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
(2021)
Review
Oncology
Catherine Alix-Panabieres, Klaus Pantel
Summary: CTC and ctDNA have been recognized as promising biomarkers with various clinical applications, including early cancer detection and therapeutic monitoring. However, challenges such as standardization and validation of clinical effectiveness need to be addressed in this dynamic field of translational cancer research.
Review
Biotechnology & Applied Microbiology
Yiming Meng, Jing Sun, Yang Zheng, Guirong Zhang, Tao Yu, Haozhe Piao
Summary: Liquid biopsy, a new diagnostic concept, has changed the clinical practice of oncology by analyzing genetic material in platelets. This emerging method can replace and supplement current tumor detection methods, providing a novel theoretical basis for clinical tumor diagnosis. Further research on the role of platelets in tumor diagnosis will help advance clinical practice in this area.
ONCOTARGETS AND THERAPY
(2021)
Review
Oncology
Ladina Greuter, Nicole Frank, Raphael Guzman, Jehuda Soleman
Summary: Liquid biopsy can diagnose and monitor pediatric brain tumors by analyzing circulating DNA in blood, cerebrospinal fluid, or urine. It shows promise in characterizing high-grade gliomas and predicting tumor progression. However, more research is needed to standardize its use for pediatric brain tumors.
Article
Oncology
Darshana Patil, Dadasaheb Akolkar, Rajnish Nagarkar, Navin Srivastava, Vineet Datta, Sanket Patil, Sachin Apurwa, Ajay Srinivasan, Rajan Datar
Summary: Liquid biopsy-based multi-analyte profiling in peripheral blood can assist in the selection of treatment regimens for patients with refractory cancers, leading to positive disease control rates.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Varsha Tulpule, Gareth J. Morrison, Mary Falcone, David I. Quinn, Amir Goldkorn
Summary: This review outlines current data on liquid biopsies and their application in the clinical management of metastatic prostate cancer. Research findings suggest that liquid biopsies have significant potential in guiding prognosis, treatment selection, and resistance monitoring in metastatic prostate cancer. Further validation is needed to incorporate liquid biopsies into standard clinical practice.
CURRENT ONCOLOGY REPORTS
(2022)
Review
Medicine, Research & Experimental
Siobhan Connal, James M. Cameron, Alexandra Sala, Paul M. M. Brennan, David S. S. Palmer, Joshua D. D. Palmer, Haley Perlow, Matthew J. J. Baker
Summary: Cancer is a global pandemic, causing significant burdens on individuals, families, and healthcare systems. Lack of screening programs and compliance challenges contribute to the high death rate of cancer worldwide. Liquid biopsy strategies for early detection of cancer are not sensitive enough, and early detection is crucial for better outcomes. This review examines the current market of liquid biopsy and explores the potential of combining spectroscopic and -omic methodologies for more efficient cancer diagnostics.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Clinical Neurology
Hallie Gaitsch, Robin J. M. Franklin, Daniel S. Reich
Summary: This article reviews recent developments in the application of cell-free DNA-based liquid biopsies to neurological diseases, including CNS tumours, stroke, traumatic brain injury, Alzheimer's disease, epilepsy, multiple sclerosis, and neuroinfectious disease. The article discusses the types of liquid biopsy targets, methods used to identify and probe potential liquid biomarkers, and recent applications of such biomarkers to a variety of complex neurological conditions. The challenges and opportunities for translating liquid biopsies to use in clinical neurology settings are also discussed.
Review
Oncology
Isabel Heidrich, Lucija Ackar, Parinaz Mossahebi Mohammadi, Klaus Pantel
Summary: Liquid biopsy (LB) presents broad opportunities in oncology, allowing early detection, risk assessment, and monitoring of cancer therapies with comprehensive and real-time information. Circulating tumor cells (CTCs) and circulating tumor-derived DNA (ctDNA) are key LB markers for breast, prostate, lung, and colorectal cancer. Current implementation of LB in clinical practice is hindered by methodological and biological limitations.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Marcel Kemper, Carolin Krekeler, Kerstin Menck, Georg Lenz, Georg Evers, Arik Bernard Schulze, Annalen Bleckmann
Summary: Liquid biopsy is a novel method in cancer diagnostics that is less invasive for patients compared to conventional tissue biopsies. This review provides an overview of lung cancer biomarkers identified in liquid biopsy assays and discusses the differences, current applications, and future perspectives of liquid biopsies in lung cancer.
Article
Oncology
Sandeep Sisodiya, Vishakha Kasherwal, Asiya Khan, Bishnudeo Roy, Anjana Goel, Sandeep Kumar, Nazneen Arif, Pranay Tanwar, Showket Hussain
Summary: Late detection and lack of precision diagnostics pose major challenges in cancer prevention and management. Liquid biopsies offer a non-invasive or minimally invasive method for identifying biomarkers in solid malignancies, enabling early diagnosis, prognosis prediction, and targeted therapeutics. However, there are challenges to be addressed in their implementation, and further research is needed for future development.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Laura E. Fischer, Sebastian Stintzing, Volker Heinemann, Ulrich Keilholz, Dietmar Keune, Claudia Vollbrecht, Thomas Burmeister, Andreas Kind, Lena Weiss, David Horst, Thomas Kirchner, Frederick Klauschen, Andreas Jung, Christoph Benedikt Westphalen, Ivan Jelas
Summary: This study retrospectively analyzed the implementation of liquid biopsies (LB) in the clinical management of colorectal cancer (CRC) patients between 2017 and 2021. The results indicate that the potential of LB as a diagnostic tool to drive personalized treatment in CRC patients is not yet fully exploited in everyday clinical practice.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Joao Lobo, Ricardo Leao, Carmen Jeronimo, Rui Henrique
Summary: Liquid biopsies are a minimally invasive means of managing cancer patients, including early diagnosis and prediction of response to therapy. In the field of germ cell tumors, liquid biopsies are invaluable due to the lack of invasive diagnostic tissue biopsies. Current liquid biopsy-based biomarkers for this disease include serum tumor markers, microRNAs, cell-free DNA markers, and circulating tumor cells. Novel strategies and challenges for liquid biopsy markers and methodologies are being explored, providing insight into the future directions for liquid biopsy tests in this field.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Urology & Nephrology
Irene Casanova-Salas, Alejandro Athie, Paul C. Boutros, Marzia Del Re, David T. Miyamoto, Kenneth J. Pienta, Edwin M. Posadas, Adam G. Sowalsky, Arnulf Stenzl, Alexander W. Wyatt, Joaquin Mateo
Summary: Liquid biopsy has emerged as a practical tool to profile tumor dynamics over time, elucidating features that evolve with tumor progression. Blood-based liquid biopsies have demonstrated promise as prognostic and response biomarkers in both localized tumors and advanced disease.